Nutriband

NTRB · NASDAQ

$5.85−$0.15 (−2.50%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.00

About NTRB

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees: 13
Headquarters: Orlando, Florida
Listed: Jun 20, 2017
Sector: Health Care
Industry: Pharmaceuticals
Website: nutriband.com

Leadership

Nutriband executives
Name	Title	Since	Age
Serguei Melnik	—	2016	52
Gareth Sheridan	—	2016	35
Gerald Goodman	—	—	77
Alan Smith	—	—	58
Jeff Patrick	—	—	55
Radu Bujoreanu	—	—	55
Sergei Glinka	—	—	59
Irina Gram	—	—	37
Mark Hamilton	—	—	38
Stefani Mancas	—	—	48

Revenue by product and region

Fiscal year ended Jan 31, 2021: $943.70K total revenue

By region

Foreign [Member]$583.32K61.8%
United States [Member]$360.38K38.2%

Similar companies

Companies in the same industry as Nutriband

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.